跳至主要内容
临床试验/NCT01864343
NCT01864343已完成不适用

Target Temperature Management In Myocardial Infarction - A Pilot Study

Medical University of Vienna1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2011年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
19
试验地点
1
主要终点
Feasibility of a combined cooling strategy for achieving a core temperature of <35.0°C at the time of reperfusion of the infarct related artery

研究概览

简要总结

The primary goal in the treatment of acute myocardial infarction is to reperfuse the ischemic myocardium to reduce infarct size. Animal data and human data suggest that whole-body cooling to temperatures below 35°C before revascularisation can additionally reduce infarct size and therefore improves outcome in these patients.

The purpose of the study is to determine the feasibility and safety of a combined cooling strategy started in the out-of-hospital arena for achieving pre-reperfusion hypothermia in patients with acute st-elevation myocardial infarction.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age between 18 and 75 years
  • •Immediately transfer to cath-lab is possible
  • •Anterior or inferior ST-Elevation myocardial infarction
  • •ST-Segment elevation of >0.2mV in 2 or more anatomically contiguous leads
  • •Duration of symptoms <6 hours

排除标准

  • •Participation in another study
  • •Patients presenting with cardiac arrest
  • •Tympanic temperature of <35.0°C prior enrolment
  • •Thrombolysis therapy
  • •Previous myocardial infarction in medical history
  • •Previous percutaneous coronary intervention or coronary artery bypass graft
  • •Severe heart failure (defined as a New York Heart Association (NYHA) score of III or IV), Killip class II through IV at presentation
  • •Clinical signs of infection
  • •End-stage kidney disease or hepatic failure
  • •Recent stroke (within the last six month)
  • •Conditions that may be exacerbated by hypothermia, such as haematological dyscrasias, oral anticoagulant treatment with international normalized radio >1.5, severe pulmonary disease
  • •Pregnancy. Women of childbearing potential are excluded
  • •Allergy to meperidine, buspirone, magnesium, or polyvinyl chloride
  • •Use of a monoamine oxidase inhibitor such as selegiline in the previous 14 days

研究组 & 干预措施

Pre- and perinterventional hypothermia

Experimental

Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.

干预措施: EMCOOLS flex pad; Philips Innercool RTx (Device)

结局指标

主要结局

Feasibility of a combined cooling strategy for achieving a core temperature of <35.0°C at the time of reperfusion of the infarct related artery

时间窗: Time of reperfusion of the culprit lesion in st-elevation myocardial infarction (expected average 120 minutes)

Blood temperature will be recorded at the time of first wire-crossed lesion of the infarct related coronary stenosis

次要结局

  • Tolerability of a combined cooling strategy as an adjunctive therapy on primary percutaneous coronary intervention in acute st-elevation myocardial infarction(during active cooling and rewarming (in average the first 4 hours))
  • Time to revascularisation (first medical contact to balloon time)(Time of reperfusion (in average 120 minutes))
  • Safety of a combined cooling strategy as an adjunctive therapy on primary percutaneous coronary intervention in acute st-elevation myocardial infarction(within 45 days (+/- 15 days))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Christoph Testori

Department of Emergency Medicine

Medical University of Vienna

研究点 (1)

Loading locations...

相似试验